Phase 2 N=36 Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma · Contiguous Stage II Grade 2 Follicular Lymphoma · Contiguous Stage II Marginal Zone Lymphoma
Primary: Progression-free Survival — 92; 71; 83; 71 Kaplan-Meier estimated % of patients
Phase 2 N=30 A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Phase 2 N=70 Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Low-grade B Cell Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…
Phase 2 N=26 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Phase 2 N=42 Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
Non-Hodgkin's Lymphoma
Primary: Overall Response Rate (Complete Response and Partial Response) After Three Inductions Cycles of Treatment. — 71 percentage of patients
Phase 2 N=56 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Phase 2 N=77 Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…
Phase 2 N=765 Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 2 N=21 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants
Phase 3 N=545 Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Lymphoma
Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33
Phase 2 N=38 A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants
Phase 2 N=31 Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Low-Grade Lymphoma
Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants
Phase 2 N=30 Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Unconfirmed Response (Complete Response, Complete Response/Unconfirmed, or Partial Response), as Assessed by the Investigator — 30…
Phase 2 N=103 Bortezomib in Treating Patients With Lymphoproliferative Disorders
Recurrent Grade 1 Follicular Lymphoma · Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 3 Follicular Lymphoma
Primary: Response Rate — 11; 6 participants
Phase 2 N=55 Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
Lymphoma
Primary: Complete Response Rate — 65 percentage of evaluable participants
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 2 N=78 A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=37 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Response Rate — 29 percentage of participants
Phase 2 N=39 Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Lymphoma, B-Cell
Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants
Phase 2 N=25 A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Primary: Overall Response Rate — 12 Participants — p=0.044
Phase 2 N=21 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants
Phase 2 N=156 Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
Ann Arbor Stage III Grade 1 Follicular Lymphoma · Ann Arbor Stage III Grade 2 Follicular Lymphoma · Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
Primary: Number of Participants With Best Overall Disease Response — 0; 56; 17; 8 Participants
Phase 2 N=41 Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants
Phase 2 N=33 Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Lymphoma
Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 3; 1; 0; 0 Participants
Phase 2 N=59 Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Phase 2 N=67 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Phase 2 N=20 Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants